Babcock & Wilcox Enterprises, Inc. (BW) Form 10-Q — Aug 10, 2026
Babcock & Wilcox posted a breakout second quarter: revenue more than doubled to $319.7 million from $138.9 million a year ago, and continuing operations swung to income of $14.3 million ($0.07 diluted EPS) versus a $7.4 million loss in Q2 2025, with Adjusted EBITDA up to $21.8 million from $13.9 million. The surge is anchored by the $2.4 billion Base Electron agreement signed in February 2026 to design and install four 300-megawatt natural gas-fired power plants serving an AI factory tied to Applied Digital; it contributed $100.7 million of Q2 revenue and drove total backlog to $2.57 billion, up from $405.6 million a year earlier.
Key figures
- Eps
- $0.07 Q2 2026 diluted (vs -$0.63 Q2 2025); -$0.51 1H 2026
- Revenue
- $319.7 million Q2 2026 (vs $138.9M Q2 2025); $534.1 million 1H 2026
- Net Income
- $14.3 million Q2 income from continuing operations; -$62.7 million 1H net loss
- Total Debt
- $276.8 million
- Revenue Yoy
- +130% Q2; +86% 1H
- Total Assets
- $999.6 million
- Cash Position
- $308.6 million cash and equivalents ($382.8 million including restricted)
- Shares Outstanding
- 148965066
- Backlog
- $2.57 billion at June 30, 2026 (vs $405.6 million a year earlier)
- Bookings 1h2026
- $2.663 billion
- Adjusted ebitda q2
- $21.8 million (vs $13.9 million Q2 2025)
- Buyback authorization
- $50 million (announced July 13, 2026)
- Base electron revenue q2
- $100.7 million
- May 2026 equity offering
- 12.4 million shares for $218.2 million net proceeds
- Customer warrant liability
- $136.9 million
- Preferred stock outstanding
- $191.7 million gross
- Base electron contract value
- $2.4 billion
- Senior notes 2026 redemption
- $61.4 million (redeemed August 13, 2026)
- Warrant fair value charge 1h
- $64.4 million non-cash expense
Price after filing
Close on the filing date to close N calendar days later (from $9.37). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.